<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935075</url>
  </required_header>
  <id_info>
    <org_study_id>2016-M-1</org_study_id>
    <nct_id>NCT02935075</nct_id>
  </id_info>
  <brief_title>Optimization of Antiretroviral Therapy</brief_title>
  <acronym>OAT</acronym>
  <official_title>Optimization of Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yunnan Provincial Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Nanjing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination antiretroviral therapy (cART) inhibit HIV replication effectively. However,
      synergy among these drugs has not been well considered. The dose of drugs used as monotherapy
      is the same as that used in combination therapy. Tenofovir+lamivudine+efavirenz is still the
      first line regimen of cART in developing countries. The side effects of these drugs are
      related to the concentration of drugs. Based on our previous data, we aim to evaluate whether
      reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects
      while not scarifying their virological efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with HIV viral road &lt; 50 copies/ml</measure>
    <time_frame>48 weeks</time_frame>
    <description>calculate the percentage of patients who with HIV viral road ＜50 copies/ml every month in two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cell Differentiation 4 (CD4) T cell counts</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence of adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Reduced dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>Oral daily</description>
    <arm_group_label>Reduced dose</arm_group_label>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Oral daily</description>
    <arm_group_label>Reduced dose</arm_group_label>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Oral daily</description>
    <arm_group_label>Reduced dose</arm_group_label>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV antibody positive

          -  Chinese nationality

          -  Naïve to antiretroviral therapy

          -  Willing to start antiretroviral therapy

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Pregnant, breastfeeding, or lactating

          -  Females try to get pregnant during the research period

          -  Subjects who allergic to any of the research drugs

          -  Subjects that taking other drugs that known to impact the absorption, distribution,
             metabolism and excretion of the research drugs

          -  Any serious or active medical or psychiatric illness which, in the opinion of the
             Investigator, would interfere with treatment, assessment, compliance with the
             protocol, or subject safety. This would include any active clinically significant
             renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease)
             illness, or malignancy

          -  Medical or psychiatric condition or occupational responsibilities that may preclude
             compliance with the protocol

          -  Laboratory blood values:

          -  Haemoglobin &lt;9.0 grams/decilitre (g/dL)

          -  Neutrophil count &lt;1500/mm3

          -  Platelet count &lt;75,000/mm3

          -  Aspartate aminotransferase or Alanine transaminase &gt;3 times Upper Limit of Normal
             (ULN)

          -  Total bilirubin &gt;3 times Upper Limit of Normal (ULN)

          -  Subjects with an estimated creatinine clearance of &lt;90 mL/minute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongzhou Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Public Health Clinical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Chen</last_name>
    <phone>0086-21-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>chenjun@shaphc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiliang Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Chen</last_name>
      <phone>008602137990333</phone>
      <phone_ext>3222</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan AIDS care center</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xicheng Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

